Jingsong Zhang, MD
Enriched profileInterim Vice Chair, Department of Genitourinary Oncology, Moffitt Cancer Center · Moffitt Cancer Center
Jingsong Zhang is Interim Vice Chair, Department of Genitourinary Oncology, Moffitt Cancer Center at Moffitt Cancer Center. OpenAlex indexes 368 publications with 6,609 citations (h-index 34); ClinicalTrials.gov lists 15 registered studies with this person as an investigator.
Data verified 24 Oct 2026
Overview
Updated 25 Oct 2026
Jingsong Zhang, M.D., is Interim Vice Chair, Department of Genitourinary Oncology, Moffitt Cancer Center. The public record shows 368 publications with 6,609 citations (h-index 34), centered on Prostate Cancer Treatment and Research, Cancer Immunotherapy and Biomarkers, PARP inhibition in cancer therapy. It also documents an investigator role on 15 registered clinical trials, industry payments reported by 26 companies.
- Most recent indexed publication: 2026 · Nature communications
- Top research focus: Prostate Cancer Treatment and Research
- 15 registered trials on ClinicalTrials.gov
- Open Payments reporting from 26 companies
Generated from the cited public record · current as of 25 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 18 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 78.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 25 Oct 2026
Listed as an investigator on 15 registered studies on ClinicalTrials.gov. The most recent:
- Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Industry payments
Updated 25 Oct 2026
26 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year20259 payments
- AstraZeneca Pharmaceuticals LPProgram year20258 payments
- AVYXA PHARMA, LLCProgram year20256 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
53%Androgen Receptor Inhibitor26.8%Bicalutamide75%Xtandi25%Part D≥53 patientsCytochrome P450 17A1 Inhibitor14.8%Abiraterone Acetate100%Part D≥20 patients+ 2 more classes in this area
Metabolism & gastrointestinal
17.3%Corticosteroid17.3%Prednisone100%Part D≥45 patientsNervous system
16.2%Phenothiazine8.3%Prochlorperazine Maleate100%Part D≥35 patientsOpioid Agonist4.6%Tramadol Hcl58%Oxycodone Hcl42%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 25 Oct 2026
93 congress contributions (2011–2026) across AACR, ASCO, ASTRO, ENDO, SABCS per OpenAlex. The most recent:
- A multicenter, open-label, phase II study of adaptive combination immunotherapy with VEGFR-TKI for advanced renal cell carcinoma.
ASCO Annual Meeting
ASCO2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 25 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Pembrolizumab plus high-dose IL-2 in advanced clear cell renal cell carcinoma: six-year survival outcomes and molecular signatures from a phase 2 trial.
Nature communications
Clinical Trial2026 - Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial.
Nature medicine
Clinical Trial2025 - Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway).
Clinical cancer research
Clinical Trial2024
Most-cited works
by citation count (OpenAlex)Network
Updated 25 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 25 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
PhD
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →moffitt.org ↗ - Medical degree
Peking Union Medical College (China)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →moffitt.org ↗ - PhD in pathology
University of Southern California
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →moffitt.org ↗
Secondary affiliations
appointments beyond the home institution- Professor
University of South Florida College of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →moffitt.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Ignacio Wistuba, MD
Moffitt Cancer Center
Christine Chung, MD
Moffitt Cancer Center
Jonathan Strosberg, MD
Moffitt Cancer Center
Nikhil Khushalani, MD
Moffitt Cancer Center
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Toni Choueiri, MD
Dana-Farber Cancer Institute
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Fred Saad, MD
Centre hospitalier de l'Université de Montréal (CHUM)